China’s Kelun Expects ADC Strategy To Deliver By Balancing Safety, Efficacy
Major Merck Deals
Executive Summary
After inking recent jumbo licensing deals with Merck & Co., Kelun sheds more light on a partnership that traces back to 2020. The Chinese generics-focused firm also elaborates on the design rationale behind its antibody-drug conjugate programs, including the potential competitive benefits of its asset targeting Claudin 18.2.
You may also be interested in...
Kelun Highlights First-Line Plans For Merck-Partnered Trop2 ADC
To differentiate from Daiichi Sankyo/AstraZeneca's Dato-DXd, Kelun and Merck & Co. are targeting the first-line treatment of EGFR wild-type NSCLC with a combination of their antibody-drug conjugate SKB-264 (MK-2870) with an anti-PD-1 antibody. Additionally, Kelun as the sole sponsor is advancing a Phase III study of the ADC as a monotherapy for second-line EGFR inhibitor-failed NSCLC.
Chinese Language Podcast: 集采, ADC交易, 基因编辑出口和中国生物制药内在矛盾
Recent major ADC deals, volume-based procurement (Jicai), China’s plan to ban gene-editing technology exports and the biotech paradox in China are the main topics for this new China Biotech Hot Topic podcast. Brian Yang and Dexter Yan discuss key aspects to watch and the implications for major players as well as the wider pharma sector.
Astellas Reports Second Phase III Win With Zolbetuximab In Stomach Cancer
The anti-Claudin-18.2 agent plus chemotherapy improves progression-free survival in inoperable or metastatic stomach cancer, following a similar Phase III readout in November.